AEON Biopharma
AEON
73 hedge funds and large institutions have $213M invested in AEON Biopharma in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
1.91% more ownership
Funds ownership: 76.82% → 78.73% (+1.9%)
1% more funds holding
Funds holding: 72 → 73 (+1)
3% more capital invested
Capital invested by funds: $207M → $213M (+$5.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$5.51M |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
+$2.91M |
| 3 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$2.45M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.29M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
-$5.51M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.89M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$1.22M |
| 4 |
JP Morgan Chase
New York
|
-$1.01M |
| 5 |
AR
Advisory Research
Chicago,
Illinois
|
-$991K |
AEON Hedge Fund Activity: Q2 2022 in Review
73 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q2 2022, worth a combined $213M — up 2.7% from $207M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new AEON positions and 6 closed out — a net gain of 1 holder — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $5.51M. The largest seller was Linden Advisors, cutting an estimated $5.51M.
- 73 institutional investors held AEON Biopharma (AEON) as of Q2 2022, up from 72 in Q1 2022.
- Funds reported $213M of AEON Biopharma stock for Q2 2022, up 2.7% quarter-over-quarter.
- 7 funds opened new AEON Biopharma positions in Q2 2022 and 6 closed out, a net change of +1 holder.
- The largest AEON Biopharma buyer in Q2 2022 was Bank of Montreal, an estimated $5.51M added.
- The largest AEON Biopharma seller in Q2 2022 was Linden Advisors, an estimated $5.51M sold.
Based on aggregated 13F filings for Q2 2022.